Skip to main content

Advertisement

SpringerLink
Log in

Neurologic Manifestations of Systemic Disease: Movement Disorders

  • Neurologic Manifestations of Systemic Disease (D Lapides, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

To summarize the state of the art of therapeutic approaches for movement disorders occurring in the context of systemic disorders. These secondary movement disorders, e.g., parkinsonism, tremor, chorea, dystonia, ballism, ataxia, and dyskinesia, among others, can be transitory manifestations of systemic diseases or part of syndromes that combine systemic and neurological symptoms (e.g., Wilson’s disease). These conditions are frequently treatable and in certain cases also curable. Therefore, their recognition and treatment impact the outcomes of these patients.

Recent findings

Most current knowledge on this topic is based on cohort studies and single case reports. There are a few large studies mostly in the context of movement disorders in cerebrovascular disease and Wilson’s disease.

Summary

The management of movement disorders due to systemic disease is mostly achieved by treatment of the systemic conditions together with appropriate medical and surgical treatments for each manifestation. Specific considerations must be taken into account when managing the medications commonly used for movement disorders in the context of systemic disease compared to primary degenerative processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Czlonkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Nature reviews disease primers article: Wilson disease. Nat. Rev. Dis. Prim. 2018;4:21.

    Article  PubMed  Google Scholar 

  2. Schwendimann RN, Minagar A. Liver disease and neurology. Continuum (Minneap Minn). 2017;23(3, Neurology of Systemic Disease):762–77.

    PubMed  Google Scholar 

  3. Bally JF, Méneret A, Roze E, Anderson M, Grabli D, Lang AE. Systematic review of movement disorders and oculomotor abnormalities in Whipple’s disease. Mov Disord. 2018;33(11):1700–11.

    Article  PubMed  Google Scholar 

  4. Shah BB, Lang AE. Acquired neurosyphilis presenting as movement disorders. Mov Disord. 2012;27(6):690–5.

    Article  PubMed  Google Scholar 

  5. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov. Disord. 2018;33:75–87.

    Article  PubMed  Google Scholar 

  6. Fung VS, Duggins A, Morris JG, Lorentz IT. Progressive myoclonic ataxia associated with celiac disease presenting as unilateral cortical tremor and dystonia. Mov Disord. 2000;15(4):732–4.

    Article  CAS  PubMed  Google Scholar 

  7. Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov. Disord. 2009;24:2358–62.

    PubMed  Google Scholar 

  8. de Souza A. Movement disorders and the osmotic demyelination syndrome. Parkinsonism Relat Disord. 2013;19(8):709–16.

    Article  PubMed  Google Scholar 

  9. Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013;12(6):597–608.

    Article  PubMed  Google Scholar 

  10. Ondo WG. Hyperglycemic nonketotic states and other metabolic imbalances. Handb Clin Neurol. 2011;100:287–91.

    Article  PubMed  Google Scholar 

  11. Lin JJ, Chang MK. Hemiballism-hemichorea and non-ketotic hyperglycaemia. J. Neurol. Neurosurg. Psychiatry. 1994;57:748–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rozenberg E, Telman G. Reversible acute chorea in a patient with diabetes treated with hemodialysis. J. Clin. Neurosci. 2012;19:1179.

    Article  CAS  PubMed  Google Scholar 

  13. Kumar N, Rizek P, Sadikovic B, Adams PC, Jog M. Movement disorders associated with hemochromatosis. Can. J. Neurol. Sci. 2016;43:801–8.

    Article  PubMed  Google Scholar 

  14. Lin JJ, Lin GY, Shih C, Shen WC. Presentation of striatal hyperintensity on T1-weighted MRI in patients with hemiballism-hemichorea caused by non-ketotic hyperglycemia: report of seven new cases and a review of literature. J. Neural Transm. 2001;108:750–5.

    Article  Google Scholar 

  15. Oh SH, Lee KY, Im JH, Lee MS. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study a meta-analysis of 53 cases including four present cases. J. Neurol. Sci. 2002;200:57–62.

    Article  PubMed  Google Scholar 

  16. Hefter H, Mayer P, Benecke R. Persistent chorea after recurrent hypoglycemia: a case report. Eur. Neurol. 1993;33:244–7.

    Article  CAS  PubMed  Google Scholar 

  17. Lai SL, Tseng YL, Hsu MC, Chen SS. Magnetic resonance imaging and single-photon emission computed tomography changes in hypoglycemia-induced chorea. Mov. Disord. 2004;19:475–8.

    Article  PubMed  Google Scholar 

  18. Wolz M, Reichmann H, Reuner U, Storch A, Gerber J. Hypoglycemia-induced choreoathetosis associated with hyperintense basal ganglia lesions in T1-weighted brain MRI. Mov Disord. 2010 May 15;25(7):966–8.

  19. Paraskevas GP, Vlachos GS, Vassilopoulou S, Anagnostou E, Spengos K, Zis V. Hypoglycemia-induced hemichorea in a patient with Fahr’s syndrome. Neurol. Sci. 2012;33:1397–9.

    Article  PubMed  Google Scholar 

  20. Lee D, Lee D, Ahn TB, Hong IK, Kim DY. Recurrent hemichorea after a hypoglycemic episode. Parkinsonism Relat Disord. 2014;20(6):676–7.

    Article  PubMed  Google Scholar 

  21. Guerrero WR, Okun MS, McFarland NR. Encephalopathy, hypoglycemia, and flailing extremities: a case of bilateral chorea-ballism associated with diabetic ketoacidosis. Tremor Other Hyperkinet Mov (N Y). 2012; 2:tre-02-58-235-1.

  22. Arifi B, Gupta S, Sharma S, Daraboina A, Ahuja S. A case report of chorea associated with hyperthyroidism. J Clin Diagn Res. 2016 Feb;10(2):PL01.

  23. Levy A, Lang AE. Ataxia-telangiectasia: a review of movement disorders, clinical features, and genotype correlations. Mov Disord. 2018 Aug;33(8):1238–47.

  24. Hamed SA. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Rev. Clin. Pharmacol. 2019;12:61–90.

    Article  CAS  PubMed  Google Scholar 

  25. Shin HW, Park HK. Recent updates on acquired hepatocerebral degeneration. Tremor Other Hyperkinet Mov (N Y). 2017;7:463.

    Article  Google Scholar 

  26. Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.

    Article  CAS  PubMed  Google Scholar 

  27. Jagota P, Bhidayasiri R, Lang AE. Movement disorders in patients with diabetes mellitus. J Neurol Sci. 2012 Mar 15;314(1–2):5–11.

  28. Docherty MJ, Burn DJ. Hyperthyroid chorea. Handb Clin Neurol. 2011;100:279–86.

    Article  PubMed  Google Scholar 

  29. Espay AJ. Neurologic complications of electrolyte disturbances and acid-base balance. Handb Clin Neurol. 2014;119:365–82.

    Article  PubMed  Google Scholar 

  30. Berendes K, Dörstelmann D. Unsuccessful treatment with levodopa of a parkinsonian patient with calcification of the basal ganglia. J. Neurol. 1978;218:51–4.

    Article  CAS  PubMed  Google Scholar 

  31. Pearson DWM, Fogelman I, Durward WF, Boyle IT, Beastall G. Pseudohypoparathyroidism presenting as severe Parkinsonism. Postgrad. Med. J. 1981;57:445–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Song CY, Zhao ZX, Li W, Sun CC, Liu YM. Pseudohypoparathyroidism with basal ganglia calcification. Medicine (Baltimore). 2017;96(11):e6312.

    Article  PubMed  PubMed Central  Google Scholar 

  33. N G-J, MR H. J C. Dopa-resistant parkinsonism, oculomotor disturbances, chorea, mirror movements, dyspraxia, and dementia: the expanding clinical spectrum of hypoparathyroidism. Mov Disord. 2000 Nov;15(6):1273–6.

  34. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.

    Article  PubMed  Google Scholar 

  35. Duyff RF. Van Den Bosch J, Laman DM, Potter Van Loon BJ, Linssen WHJP. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J. Neurol. Neurosurg. Psychiatry. 2000;68:750–5.

    CAS  Google Scholar 

  36. Frame B. Parkinsonism in postoperative hypoparathyroidism. Arch. Intern. Med. 1965;116:424–7.

    Article  CAS  PubMed  Google Scholar 

  37. Augusto CMG, de Morais NS, Santana RP, de Almeida MOP. Parkinsonism as an atypical manifestation of primary hyperparathyroidism. AACE Clin. Case Reports. 2019; 5:e244–e246.

  38. Hirooka Y, Yuasa K, Hibi K, Ishikawa A, Sobue G, Naruse T, et al. Hyperparathyroidism associated with parkinsonism. Intern. Med. 1992;31:904–7.

    Article  CAS  PubMed  Google Scholar 

  39. Klawans HL, Lupton M, Simon L. Calcification of the basal ganglia as a cause of levodopa-resistant parkinsonism. Neurology. 1976;26:221–5.

    Article  CAS  PubMed  Google Scholar 

  40. Espay AJ, Chen R. Myoclonus. Continuum (Minneap Minn). 2013 Oct;19(5 Movement Disorders):1264–86.

  41. Vinagre-Aragón A, Zis P, Grunewald RA, Hadjivassiliou M. Movement disorders related to gluten sensitivity: a systematic review. Nutrients. 2018;10(8):1034.

    Article  PubMed Central  Google Scholar 

  42. Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis. and management. Orphanet J Rare Dis. 2014;9:179.

    Article  PubMed  Google Scholar 

  43. Donzuso G, Sciacca G, Nicoletti A, Mostile G, Patti F, Zappia M. Extensive bilateral striopallidodentate calcinosis: a 50 years history of hypoparathyroidism presenting like a parkinsonian syndrome. J Neurol. 2016;263(9):1876–9.

    Article  CAS  PubMed  Google Scholar 

  44. Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Movement disorders and AIDS: a review. Parkinsonism Relat Disord. 2004;10(6):323–34.

    Article  PubMed  Google Scholar 

  45. Kono S. Aceruloplasminemia: an update. Int. Rev. Neurobiol. 2013;110:125–51.

    Article  CAS  PubMed  Google Scholar 

  46. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat. Rev. Dis. Prim. 2017;3:1–21.

    Google Scholar 

  47. Chorea TP. Continuum (Minneap Minn). 2019 Aug;25(4):1001–35.

  48. Tremor LED. Continuum (Minneap Minn). 2019 Aug;25(4):959–75.

  49. Stahl CM, Frucht SJ. An update on myoclonus management. Expert Rev. Neurother. 2019 Apr;19(4):325–31.

  50. Zhang X jin X, Z yu W, cheng Y, Tan EK. Paroxysmal movement disorders: recent advances and proposal of a classification system. Park. Relat. Disord. 2019;59:131–9.

    Google Scholar 

  51. Schneider R, Karakas E, Bartsch DK, Schlosser K. The influence of parathyroidectomy on restless legs syndrome in patients with renal hyperparathyroidism. World J. Surg. 2013;37:2866–71.

    Article  PubMed  Google Scholar 

  52. Santos RSS, Coelho FMS, Da Silva BC, Graciolli FG, Dominguez WV, De Menezes Montenegro FL, et al. Parathyroidectomy improves restless leg syndrome in patients on hemodialysis. PLoS One. 2016 May 19;11(5):e0155835.

  53. Lim LL, Dinner D, Tham KW, Siraj E, Shields R. Restless legs syndrome associated with primary hyperparathyroidism. Sleep Med. 2005;6:283–5.

    Article  PubMed  Google Scholar 

  54. Dwarakanath S, Zafar A, Yadav R, Arivazhagan A, Netravathi M, Sampath S, et al. Does lesioning surgery have a role in the management of multietiological tremor in the era of Deep Brain Stimulation? Clin. Neurol. Neurosurg. 2014;125:131–6.

    Article  PubMed  Google Scholar 

  55. Sidiropoulos C, Hutchison W, Mestre T, Moro E, Prescott IA, Mizrachi AV, et al. Bilateral pallidal stimulation for Wilson’s disease. Mov. Disord. 2013;28:1292–5.

    Article  PubMed  Google Scholar 

  56. Kupsch A, Benecke R, Müller J, Trottenberg T, Schneider GH, Poewe W, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N. Engl. J. Med. 2006;355:1978–90.

    Article  CAS  PubMed  Google Scholar 

  57. Bagatti D, D’Ammando A, Franzini A, Messina G. Deep brain stimulation of the caudal zona incerta and motor thalamus for postischemic dystonic tremor of the left upper limb: case report and review of the literature. World Neurosurg. 2019;125:191–7.

    Article  PubMed  Google Scholar 

  58. Rosana A. La Rosa L. A case of hereditary haemochromatosis in a patient with extrapyramidal syndrome. Blood Transfus. 2007;5:241–3.

    PubMed  PubMed Central  Google Scholar 

  59. Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014 Feb 10;2:CD003047.

  60. Klos KJ, Ahlskog JE, Josephs KA, Fealey RD, Cowl CT, Kumar N. Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch. Neurol. 2005;62:1385–90.

    Article  PubMed  Google Scholar 

  61. Tryc AB, Goldbecker A, Berding G, Rümke S, Afshar K, Shahrezaei GH, et al. Cirrhosis-related parkinsonism: prevalence, mechanisms and response to treatments. J. Hepatol. 2013;58:698–705.

    Article  CAS  PubMed  Google Scholar 

  62. Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013 Jun;28(2):261–7.

  63. Muneta S, Fukuda H, Watanabe S, Imamura Y, Matsumoto I, Yamashita Y. Asterixis and astatic seizures in association with bilateral insular lesions in a patient with viral encephalitis. Intern. Med. 1995;34:756–61.

    Article  CAS  PubMed  Google Scholar 

  64. Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb. Clin. Neurol. 2014;119:417–32.

    Article  PubMed  Google Scholar 

  65. Hung SC, Hung SH, Tarng DC, Yang WC, Huang TP. Chorea induced by thiamine deficiency in hemodialysis patients. Am. J. Kidney Dis. 2001;37:427–30.

    Article  CAS  PubMed  Google Scholar 

  66. Lee EJ, Park JH, Ihn YK, Kim YJ, Lee SK, Park CS. Acute bilateral basal ganglia lesions in diabetic uraemia: diffusion-weighted MRI. Neuroradiology. 2007;49:1009–13.

    Article  PubMed  Google Scholar 

  67. Kiryluk K, Khan F, Valeri A. Acute chorea and bilateral basal ganglia lesions in a hemodialysis patient. Kidney Int. 2008;73:1087–91.

    Article  CAS  PubMed  Google Scholar 

  68. Dicuonzo F, Di Fede R, Salvati A, Palma M, de Mari M, Baldassarre GD, et al. Acute extrapyramidal disorder with bilateral reversible basal ganglia lesions in a diabetic uremic patient: diffusion-weighted imaging and spectroscopy findings. J. Neurol. Sci. 2010;293:119–21.

    Article  PubMed  Google Scholar 

  69. Lin JJ. Generalized chorea in the syndrome of acute bilateral basal ganglia lesions in patients with diabetic uremia. J. Clin. Neurosci. 2011;18:1266–8.

    Article  PubMed  Google Scholar 

  70. French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(Suppl 4):40–3.

    Article  PubMed  Google Scholar 

  71. Kim JS, Lee KS, Han SR, Chung YA. Decreased striatal dopamine transporter binding in a patient with extrapontine myelinolysis. Mov. Disord. 2003;18:342–5.

    Article  PubMed  Google Scholar 

  72. Barow E, Hoppe J, Mainka T, Schneider SA, Ganos C. Hematologic follow-up as clue to polycythemia vera due to JAK2 mutation presenting as late onset chorea. Mov. Disord. Clin. Pract. 2018;5:83–5.

    Article  PubMed  Google Scholar 

  73. Borg-Costanzi JM, Mohr PD, Lewis D. Primary polycythaemia presenting with chorea. Postgrad. Med. J. 1981;57:228–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Mas JL, Gueguen B, Bouche P, Derouesné C, Varet B, Castaigne P. Chorea and polycythaemia. J. Neurol. 1985;232:169–71.

    Article  CAS  PubMed  Google Scholar 

  75. Nazabal ER, Lopez JM, Perez PA, Del Corral PR. Chorea disclosing deterioration of polycythaemia vera. Postgrad. Med. J. 2000;76:658–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Midi I, Dib H, Köseoglu M, Afsar N, Günal DI. Hemichorea associated with polycythaemia vera. Neurol. Sci. 2006;27:439–41.

    Article  CAS  PubMed  Google Scholar 

  77. Marvi MM, Lew MF. Polycythemia and chorea. Handb Clin Neurol. 2011;100:271–6.

    Article  PubMed  Google Scholar 

  78. Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27–44.

    Article  PubMed  Google Scholar 

  79. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PHR, Hadjivassiliou M, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012 Feb 7;10:13.

  80. Hadjivassiliou M, Martindale J, Shanmugarajah P, Grünewald RA, Sarrigiannis PG, Beauchamp N, et al. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J. Neurol. Neurosurg. Psychiatry. 2017;88:301–9.

    Article  CAS  PubMed  Google Scholar 

  81. Hadjivassiliou M, Aeschlimann P, Sanders DS, Mäki M, Kaukinen K, Grünewald RA, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80:1740–5.

    Article  CAS  PubMed  Google Scholar 

  82. Hadjivassiliou M, Davies-Jones GAB, Sanders DS, Grünewald RA. Dietary treatment of gluten ataxia. J. Neurol. Neurosurg. Psychiatry. 2003;74:1221–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Sarrigiannis PG, Hoggard N, Aeschlimann D, Sanders DS, Grünewald RA, Unwin ZC, et al. Myoclonus ataxia and refractory coeliac disease. Cerebellum Ataxias. 2014 Sep 1;1:11.

  84. Bürk K, Melms A, Schulz JB, Dichgans J. Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol. 2001 Dec;50(6):827–8.

  85. Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019 Jun;7(5):583–613.

  86. Pereira AC, Edwards MJ, Buttery PC, Hawkes CH, Quinn NP, Giovannoni G, et al. Choreic syndrome and coeliac disease: a hitherto unrecognised association. Mov. Disord. 2004;19:478–82.

    Article  PubMed  Google Scholar 

  87. Andrade C, Rocha H, Albuquerque A, Sá MJ. Gluten chorea. Clin. Neurol. Neurosurg. 2015;138:8–9.

    Article  PubMed  Google Scholar 

  88. Walker RH. Further evidence for celiac disease-associated chorea. Tremor Other Hyperkinet Mov (N Y). 2011; 1:tre-01-32-96-3.

  89. Lefter S, Corcoran L, Mcauliffe E, Khan R, Burke L, Regan M, et al. Coeliac disease presenting with chorea. Pract. Neurol. 2020;20:144–7.

    Article  PubMed  Google Scholar 

  90. Hanagasi HA, Gürol E, Sahin HA, Emre M. Atypical neurological involvement associated with celiac disease. Eur. J. Neurol. 2001;8:67–9.

    Article  CAS  PubMed  Google Scholar 

  91. Zhang Y, Menkes DL, Silvers DS. Propriospinal myoclonus associated with gluten sensitivity in a young woman. J. Neurol. Sci. 2012;315:141–2.

    Article  PubMed  Google Scholar 

  92. Kinney HC, Burger PC, Hurwitz BJ, Hijmans JC, Grant JP. Degeneration of the central nervous system associated with celiac disease. J. Neurol. Sci. 1982;53:9–22.

    Article  CAS  PubMed  Google Scholar 

  93. Lu C -S, Thompson PD, Quinn NP, Parkes JD, Marsden CD. Ramsay hunt syndrome and coeliac disease: a new association? Mov. Disord. 1986; 1:209–219.

  94. Tison F, Arne P, Henry P. Myoclonus and adult coeliac disease. J. Neurol. 1989;236:307–8.

    Article  CAS  PubMed  Google Scholar 

  95. Chinnery FF. Reading PJ, Milne D, Gardner-Medwin D, Turnbull DM. CSF antigliadin antibodies and the Ramsay Hunt syndrome. Neurology. 1997;49:1131–3.

    Article  CAS  PubMed  Google Scholar 

  96. Smith GD, Saldanha G, Britton TC, Brown P. Neurological manifestations of coeliac disease. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):550.

  97. Sallem FS, Castro LM, Jorge C, Marchiori P, Barbosa E. Gluten sensitivity presenting as myoclonic epilepsy with cerebellar syndrome. Mov Disord. 2009 Oct 30;24(14):2162–3.

  98. Siqueira Neto JI. Leite Vieira Costa AC, Magalhães FG, Sampaio Silva G. Neurological manifestations of celiac disease. Arq. Neuropsiquiatr. 2004;62:969–72.

    PubMed  Google Scholar 

  99. Javed S, Safdar A, Forster A, Selvan A, Chadwick D, Nicholson A, et al. Refractory coeliac disease associated with late onset epilepsy, ataxia, tremor and progressive myoclonus with giant cortical evoked potentials - a case report and review of literature. Seizure. 2012;21:482–5.

    Article  PubMed  Google Scholar 

  100. Weinstock LB, Walters AS, Mullin GE, Duntley SP. Celiac disease is associated with restless legs syndrome. Dig. Dis. Sci. 2010;55:1667–73.

    Article  PubMed  Google Scholar 

  101. Moccia M, Pellecchia MT, Erro R, Zingone F, Marelli S, Barone DG, et al. Restless legs syndrome is a common feature of adult celiac disease. Mov. Disord. 2010;25:877–81.

    Article  PubMed  Google Scholar 

  102. Halac G, Hursitoglu M, Erkal H, Cakirca M, Kinas BE, Erek A, Yetmis M, Gundogan E, Tukek T CM. Prevalence of gluten sensitive enteropathy antibodies in restless legs syndrome - PubMed [Internet]. Acta Neurol Belg. 2011. p. 111(4):282–286.

  103. Manchanda S, Davies CR, Picchietti D. Celiac disease as a possible cause for low serum ferritin in patients with restless legs syndrome. Sleep Med. 2009;10:763–5.

    Article  PubMed  Google Scholar 

  104. Haddad FG, Maalouly GD, Fahed JI, Jammal MH, El Nemnoum RJ. Restless leg syndrome in a patient with celiac disease: a coincidence or an association? Ann Saudi Med. 2009;29(3):238–9.

    Article  PubMed  Google Scholar 

  105. Bago Rožanković P, Rožanković M, Romić ZČ, Bašić S. Paroxismal non-kinesigenic dyskinesia and hemidystonia associated with silent celiac disease. Clin Neurol Neurosurg. 2020 Jan;188:105586.

  106. Hall DA, Parsons J, Benke T. Paroxysmal nonkinesigenic dystonia and celiac disease. Mov. Disord. 2007;22:708–10.

    Article  PubMed  Google Scholar 

  107. Mills K, Mari Z. An update and review of the treatment of myoclonus. Curr Neurol Neurosci Rep. 2015 Jan;15(1):512.

  108. Larrosa Campo D, Ramón Carbajo C, García Urruzola F, Calleja Puerta S. Orthostatic tremor as the only manifestation of thyrotoxicosis following cerebral angiography. Neurologia. 2019 Mar;34(2):137–8.

  109. Milanov ISG. Clinical and electromyographic examination of tremor in patients with thyrotoxicosis. Int J Clin Pract. 2000 Jul-Aug;54(6):364–7.

  110. Drake ME. Paroxysmal kinesigenic choreoathetosis in hyperthyroidism. Postgrad. Med. J. 1987;63:1089–90.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Fischbeck KH, Layzer RB. Paroxysmal choreoathetosis associated with thyrotoxicosis. Ann. Neurol. 1979;6:453–4.

    Article  CAS  PubMed  Google Scholar 

  112. Yen DJ. Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia. Mov. Disord. 1998;13:361–3.

    Article  CAS  PubMed  Google Scholar 

  113. Puri V, Chaudhry N. Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism. Neurol India. 2004 Mar;52(1):102–3.

  114. Huang CW, Chen YC, Tsai JJ. Paroxysmal dyskinesia with secondary generalization of tonic-clonic seizures in pseudohypoparathyroidism. Epilepsia. 2005;46:164–5.

    Article  PubMed  Google Scholar 

  115. Prashantha DK, Pal PK. Pseudohypoparathyroidism manifesting with paroxysmal dyskinesias and seizures. Mov Disord. 2009 Mar 15;24(4):623–4.

  116. Dure IVLS, Mussell HG. Paroxysmal dyskinesia in a patient with pseudohypoparathyroidism. Mov. Disord. 1998;13:746–8.

    Article  PubMed  Google Scholar 

  117. Siejka SJ, Knezevic WV, Pullan PT. Dystonia and intracerebral calcification: pseudohypoparathyroidism presenting in an eleven-year-old girl. Aust N Z J Med. 1988;18(4):607–9.

    Article  CAS  PubMed  Google Scholar 

  118. Mahmud FH, Linglart A, Bastepe M, Jüppner H, Lteif AN. Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia. Pediatrics. 2005 Feb;115(2):e242–4.

  119. Thomas KP, Muthugovindan D, Singer HS. Paroxysmal kinesigenic dyskinesias and pseudohypo-parathyroidism type Ib. Pediatr. Neurol. 2010;43:61–4.

    Article  PubMed  Google Scholar 

  120. Salti I, Faris A, Tannir N, Khouri K. Rapid correction by 1-α-hydroxycholecalciferol of hemichorea in surgical hypoparathyroidism. J. Neurol. Neurosurg. Psychiatry. 1982;45:89–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Nakano N, Uchiyama T, Okuda T, Kitano M, Taneda M. Successful long-term deep brain stimulation for hemichorea-hemiballism in a patient with diabetes. J. Neurosurg. 2005;102:1137–41.

    Article  PubMed  Google Scholar 

  122. Benito-León J, Alvarez-Linera J, Louis ED. Neurosyphilis masquerading as corticobasal degeneration. Mov. Disord. 2004;19:1367–70.

    Article  PubMed  Google Scholar 

  123. Murialdo A, Marchese R, Abbruzzese G, Tabaton M, Michelozzi G, Schiavoni S. Neurosyphilis presenting as progressive supranuclear palsy. Mov Disord. 2000 Jul;15(4):730–1.

  124. Ho KHK, Wright CC. Underbrink MP. A rare case of laryngeal dystonia associated with neurosyphilis: response to botulinum toxin injection 1. Laryngoscope. 2011;121:147–9.

    Article  PubMed  Google Scholar 

  125. Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology. and treatment. Mov Disord. 2015 Feb;30(2):171–9.

  126. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov. Disord. 1989;4:249–60.

    Article  CAS  PubMed  Google Scholar 

  127. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct. heterogeneous clinical entity. Acta Neurol. Scand. 2001;104:63–7.

    Article  CAS  PubMed  Google Scholar 

  128. Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J. Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J. Neurol. Sci. 1997;146:109–16.

    Article  CAS  PubMed  Google Scholar 

  129. Thömke F, Weilemann SL. Poor prognosis despite successful treatment of postanoxic generalized myoclonus. Neurology. 2010;74:1392–4.

    Article  PubMed  Google Scholar 

  130. Gupta H V, Caviness JN. Post-hypoxic myoclonus: current concepts, neurophysiology, and treatment. Tremor Other Hyperkinet. Mov. (N. Y). 2016;6:409.

  131. Riboldi GM, Frucht SJ. Increasing evidence for the use of sodium oxybate in multi-drug-resistant Lance–Adams syndrome. Tremor Other Hyperkinet Mov (N Y). 2019;9:https://doi.org/10.7916/d8-rnsh-c024.

  132. Jacobi C, Koerner C, Fruehauf S, Rottenburger C, Storch-Hagenlocher B, Grau AJ. Presynaptic dopaminergic pathology in Chediak-Higashi syndrome with parkinsonian syndrome. Neurology. 2005;64:1814–5.

    Article  CAS  PubMed  Google Scholar 

  133. • Aggarwal A, Bhatt M. Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov (N Y). 2018;28;8:525. This paper summarizes the current treatments for Wilson’s disease.

  134. Litwin T, Dziezyc K, Karliński M, Chabik G, Czepiel W, Członkowska A. Early neurological worsening in patients with Wilson’s disease. J. Neurol. Sci. 2015;355:162–7.

    Article  PubMed  Google Scholar 

  135. Weiss KH, Askari FK, Czlonkowska A, Ferenci P, Bronstein JM, Bega D, et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol. Hepatol. 2017;2:869–76.

    Article  PubMed  Google Scholar 

  136. Weiss KH, Członkowska A, Hedera P, Ferenci P. Wtx101 – an investigational drug for the treatment of Wilson disease. Expert Opin. Investig. Drugs. 2018;27:561–7.

    Article  CAS  PubMed  Google Scholar 

  137. Chen JC, Chuang CH, Wang JD, Wang CW. Combination therapy using chelating agent and zinc for Wilson’s disease. J Med Biol Eng. 2015;35(6):697–708.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008 Jun;47(6):2089–111.

  139. Litwin T, Dušek P, Członkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol. 2017;142:211–23.

    Article  PubMed  Google Scholar 

  140. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Benabid AL, Cornu P, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005 Feb 3;352(5):459–67.

  141. Benabid AL, Pollak P, Hoffmann D, Gervason C, Hommel M, Perret JE, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet. 1991;337:403–6.

    Article  CAS  PubMed  Google Scholar 

  142. Elias GJB, Namasivayam AA, Lozano AM. Deep brain stimulation for stroke: current uses and future directions. Brain Stimul. 2018 Jan-Feb;11(1):3–28.

  143. Brown EG, Bledsoe IO, Luthra NS, Miocinovic S, Starr PA, Ostrem JL. Cerebellar deep brain stimulation for acquired hemidystonia. Mov. Disord. Clin. Pract. 2020;7:188–93.

    Article  PubMed  PubMed Central  Google Scholar 

  144. O’Shea SA, Elkind M, Pullman SL, Ford B. Holmes tremor due to artery of Percheron infarct: clinical case and treatment using deep brain stimulation of the vim and ZI targets. Tremor Other Hyperkinet Mov (N Y). 2020;10:https://doi.org/10.7916/tohm.v0.732.

  145. Parker T, Raghu ALB, FitzGerald JJ, Green AL, Aziz TZ. Multitarget deep brain stimulation for clinically complex movement disorders. J. Neurosurg. 2020;3:1–6.

    Article  Google Scholar 

  146. Koerbel A. Amaral AR do, Zeh HB, Wollmann E, Koerbel RFH, Moro C, et al. Treatment of hemichoreoathetosis with arrhythmic proximal tremor after stroke: the role of zona incerta as a target for deep brain stimulation. J. Mov. Disord. 2019;12:47–51.

    Article  Google Scholar 

  147. Son B, Choi J, Ko H. Globus pallidus internus deep brain stimulation for disabling diabetic hemiballism/hemichorea. Case Rep. Neurol. Med. 2017;2017:1–5.

    Google Scholar 

  148. Yamada K, Sakurama T, Soyama N, Kuratsu JI. GPi pallidal stimulation for Lance-Adams syndrome. Neurology. 2011;76:1270–2.

    Article  PubMed  Google Scholar 

  149. Asahi T, Kashiwazaki D, Dougu N, Oyama G, Takashima S, Tanaka K, et al. Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance–Adams syndrome. J Neurol. 2015 Jun;262(6):1581–3.

  150. Kobayashi K, Katayama Y, Otaka T, Obuchi T, Kano T, Nagaoka T, et al. Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia. Stereotact. Funct. Neurosurg. 2010;88:259–63.

    Article  PubMed  Google Scholar 

  151. Ramdhani RA, Frucht SJ, Kopell BH. Improvement of post-hypoxic myoclonus with bilateral pallidal deep brain stimulation: a case report and review of the literature. Tremor Other Hyperkinet. Mov. (N. Y). 2017;7:461.

    Article  Google Scholar 

  152. Starikov AS. Electrical stimulation of the brain in Wilson-Konovalov hepatocerebral dystrophy (a neuromorphological and neurophysiological analysis). Neurosci. Behav. Physiol. 2002;32:255–7.

    Article  CAS  PubMed  Google Scholar 

  153. • Beaulieu-Boire I, Aquino CC, Fasano A, Poon YY, Fallis M, Lang AE, et al. Deep brain stimulation in rare inherited dystonias. Brain Stimul. 2016;9:905–10. Larger cohort of patients assessing the efficacy of DBS in rare movement disorders.

  154. Low HL, Alexander SK, Misbahuddin A, Gillett GT. Posterior subthalamic area deep brain stimulation for treatment of tremor and dystonia in Wilson’s disease. Brain Stimul. 2019 Sep-Oct;12(5):1304–6.

  155. Georgiev D, Mehta D, Zacharia A, Vinke RS, Milabo C, Candelario J, et al. Bilateral deep brain stimulation of the globus pallidus pars interna in a patient with variant ataxia-telangiectasia. Mov. Disord. Clin. Pract. 2016;3:405–8.

    Article  PubMed  PubMed Central  Google Scholar 

  156. Martinez-Ramirez D, Hack N, Vasquez ML, Morita H, Giugni JC, Wolf JM, et al. Deep brain stimulation in a case of mitochondrial disease. Mov. Disord. Clin. Pract. 2016;3:139–45.

    Article  PubMed  Google Scholar 

  157. Aniello MS, Martino D, Petruzzella V, Eleopra R, Mancuso M, Dell’Aglio R, et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov. Disord. 2008;23:114–8.

    Article  PubMed  Google Scholar 

  158. Pelzer E, Pauls AKM, Binder E, Brunn A, Fink GR, Timmermann L. Deep brain stimulation in rapidly progressive Parkinson-dystonia syndrome due to mitochondrial disorder. Parkinsonism Relat Disord. 2012;18(5):672–4.

    Article  PubMed  Google Scholar 

  159. Kovacs N, Pal E, Balas I, Janszky J, Nagy F, Merkli H. Neurosurgical treatment of tremor in mitochondrial encephalopathy. Mov. Disord. 2006;21:2227–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, NYU Langone Health, 222 East 41st, New York, NY, 10016, USA

    Giulietta M. Riboldi MD & Steven J. Frucht MD

Authors
  1. Giulietta M. Riboldi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven J. Frucht MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulietta M. Riboldi MD.

Ethics declarations

Conflict of Interest

Giulietta M. Riboldi declares that she has no conflict of interest.

Steven J. Frucht declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by either of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Topical Collection on Neurologic Manifestations of Systemic Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riboldi, G.M., Frucht, S.J. Neurologic Manifestations of Systemic Disease: Movement Disorders. Curr Treat Options Neurol 23, 4 (2021). https://doi.org/10.1007/s11940-020-00659-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11940-020-00659-9

Keywords

Search

Navigation